AAP News Vol. 13 No. 8 August 1997, p. 2
© 1997 American Academy of Pediatrics
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content

 Previous Article  |  Next Article 

AIDS treatment

Recently approved drugs and new research offer the chance for longer survival for HIV-infected children and better prevention of mother-to-infant AIDS transmission, according to Florida researchers.

Combination drug therapy, now being tested through pediatric AIDS trials, shows the most promise for long-term survival, the study showed.

Types of therapy available include:

• nucleoside reverse transcriptase inhibitors (zidovudine (ZDV), didanosine (DDI), zalcitabine (DDC), lamivudine (3TC) and stavudine);